SEC Filing Summary: Salarius Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on March 11, 2020. The registrant is a Delaware corporation with its principal executive offices in Houston, Texas. The filing addresses a change in the date of the Company's 2020 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and does not contain financial statements.
Material Changes
The primary material change reported is the rescheduling of the 2020 Annual Meeting of Stockholders. The new date is set for June 19, 2020. This represents a change of more than 30 days from the anniversary of the 2019 Annual Meeting, triggering the disclosure requirement under Rule 14a-5(f) of the Exchange Act.
Guidance, Outlook, and Corporate Actions
- Record Date: Stockholders of record at the close of business on April 22, 2020, will be entitled to vote at the 2020 Annual Meeting.
- Proposal Deadline: The deadline for stockholders to submit proposals for inclusion in the proxy materials is March 23, 2020.
- Meeting Details: The specific time and location of the meeting will be detailed in the Company's proxy statement.
- Emerging Growth Company: The registrant has indicated it is an emerging growth company.
Key Facts for Investor Verification
- Verify the new Annual Meeting date of June 19, 2020, and the record date of April 22, 2020.
- Confirm the March 23, 2020 deadline for submitting shareholder proposals.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.
- Ensure the registrant name is Salarius Pharmaceuticals, Inc. (Ticker: SLRX), as the input metadata referenced Decoy Therapeutics Inc. incorrectly.